International Journal on Science and Technology (IJSAT)
E-ISSN: 2229-7677 ● Website: www.ijsat.org ● Email: editor@ijsat.org

Nanomedicine in Cancer Therapy: Targeted Approaches for Improved Efficacy

Nutan Pagar[1], Nilesh Shewale[2], Pankaj Patil[3], Sanket Jadhav[4], Mayur Gangurde[5]

Swami Institute of Pharmacy, Abhona

Abstract:

Nanomedicine has revolutionized cancer therapy by enabling targeted drug delivery, improved therapeutic efficacy, and reduced systemic toxicity. This review explores the latest advancements in nanomedicine for cancer treatment, focusing on targeted approaches such as passive, active, and stimuli-responsive drug delivery systems. Passive targeting exploits the enhanced permeability and retention (EPR) effect, while active targeting utilizes ligand-functionalized nanoparticles for precise tumor recognition. Stimuli-responsive nanocarriers further enhance selectivity by triggering drug release in response to Ph, redox conditions, temperature, or enzymes. Additionally, recent innovations such as nanoparticle-based immunotherapy, combination therapy, and theranostic nanoplatforms have significantly improved treatment outcomes. Despite these advancements, challenges such as biocompatibility, large-scale manufacturing, and clinical translation remain obstacles to widespread clinical adoption. Future research should focus on personalized nanomedicine, AI-driven nanoparticle design, and hybrid nanosystems to enhance efficacy and accelerate clinical integration.

Key Words: Targeted Drug Delivery, Stimuli-Responsive Nanocarriers, CancerNanotheranostics, Nanoparticle-Based Immunotherapy, Personalized Nanomedicine

1. Introduction:

Cancer is a multifaceted disease characterized by uncontrolled cellular proliferation, resistance to apoptosis (programmed cell death), and the ability to invade surrounding tissues and metastasize to distant organs. [1] It remains a major global health concern, contributing significantly to morbidity and mortality. Despite advancements in diagnostic and therapeutic strategies, the effective management of cancer remains challenging due to its heterogeneous nature, genetic mutations, and adaptability to treatments. [2]

1.1 Challenges in Conventional Cancer Therapies:

Traditional cancer treatment approaches—surgery, chemotherapy, and radiation therapy—have played a crucial role in cancer management. However, these treatments present several limitations: Surgery: Effective for solid tumors but inadequate for metastatic cancers. Additionally, incomplete removal of malignant tissues can lead to recurrence.

- Chemotherapy: Involves the systemic administration of cytotoxic drugs, which target rapidly dividing cells. However, this approach lacks specificity, often affecting healthy tissues such as bone marrow,

hair follicles, and the gastrointestinal tract, leading to severe side effects like immunosuppression, alopecia, nausea, and organ toxicity. Moreover, multidrug resistance (MDR) developed by cancer cells significantly reduces chemotherapy efficacy. [3]

- Radiation Therapy: Though effective in localized tumors, radiation therapy can cause damage to surrounding healthy tissues, leading to long-term side effects such as fibrosis, secondary malignancies, and radiation-induced inflammation. [4]

Due to these limitations, researchers have been exploring targeted and less toxic treatment approaches to improve cancer therapy outcomes.

1.2 Role of Nanomedicine in Cancer Therapy:

Nanomedicine, a specialized branch of nanotechnology applied to medical science, has transformed cancer treatment by offering targeted, controlled, and efficient drug delivery systems. [5] Nanoparticles used in cancer therapy act as drug carriers that enhance drug solubility, bioavailability, and circulation time, ensuring a more precise accumulation of therapeutic agents in tumor tissues while reducing off-target effects.

Advantages of Nanomedicine in Cancer Treatment:

- Enhanced Drug Solubility: Many anticancer drugs exhibit poor water solubility, limiting their absorption and efficacy. Nanocarriers improve drug stability and dissolution.
- Prolonged Circulation Time: Nanoparticles can be modified with polyethylene glycol (PEG) coatings, preventing immune system recognition and rapid clearance.
- Passive and Active Targeting: Nanocarriers utilize the Enhanced Permeability and Retention (EPR) effect to passively accumulate in tumors due to their leaky vasculature. Additionally, surface modifications with tumor-specific ligands, antibodies, or aptamers enable active targeting of cancer cells.
- Controlled and Sustained Drug Release: Many nanocarriers allow pH-sensitive, enzymesensitive, or stimulus-responsive drug release, ensuring efficient delivery at the tumor site while minimizing systemic toxicity.
- Overcoming Drug Resistance: Nanoparticles help bypass drug efflux pumps in resistant cancer cells, enhancing drug accumulation and effectiveness. [6]

1.3 Scope of the Review:

This review explores various nanomedicine-based strategies for cancer therapy, focusing on different types of nanocarriers, their mechanisms of action, and their role in improving therapeutic efficacy. [7] Additionally, the article discusses the advantages, challenges, and future prospects of nanomedicine in oncology. By integrating innovative nanotechnology-based approaches, researchers aim to develop more efficient, safer, and patient-friendly cancer treatments that can revolutionize current clinical practices. [8]

2. Nanocarriers in Cancer Therapy:

Nanocarriers have revolutionized cancer therapy by improving drug solubility, stability, bioavailability, and controlled release. These nanoscale delivery systems enhance therapeutic efficacy while minimizing systemic toxicity by ensuring targeted drug accumulation in tumor tissues. Various types of nanocarriers have been developed, each with unique properties that contribute to more efficient and safer cancer treatment. [9]



2.1 Liposomes:

Liposomes are spherical, bilayer vesicles composed of phospholipids, capable of encapsulating both hydrophilic and hydrophobic drugs. Due to their structural similarity to biological membranes, they offer biocompatibility, reduced immunogenicity, and enhanced drug retention.

Advantages of Liposomes in Cancer Therapy:

- Enhanced Drug Stability: Liposomes protect encapsulated drugs from enzymatic degradation and premature clearance.
- Controlled and Prolonged Drug Release: They can be engineered for sustained drug release, ensuring prolonged therapeutic action.
- Reduced Toxicity: By targeting tumor sites, liposomes minimize exposure to healthy tissues, reducing side effects like cardiotoxicity in chemotherapy.

Clinical Applications:

Several liposomal formulations have been approved for cancer treatment:

- Doxil® (liposomal doxorubicin): Used in ovarian cancer, Kaposi's sarcoma, and multiple myeloma. Its PEGylated coating prevents rapid clearance, prolonging circulation.
- DaunoXome® (liposomal daunorubicin): Designed for the treatment of HIV-associated Kaposi's sarcoma, improving drug accumulation in tumors.

Liposomal technology has significantly enhanced the efficacy and safety profile of chemotherapy agents, making it a promising platform for targeted drug delivery. [10]

2.2 Polymeric Nanoparticles:

Polymeric nanoparticles (PNPs) are composed of biodegradable polymers such as poly(lactic-coglycolic acid) (PLGA), chitosan, and polyethylene glycol (PEG). These nanoparticles function as efficient drug carriers by providing sustained and controlled drug release, ensuring prolonged therapeutic action.

Advantages of Polymeric Nanoparticles:

- Improved Circulation Time: PEGylated polymeric nanoparticles, also known as stealth nanoparticles, evade immune detection, leading to extended systemic retention.
- Enhanced Tumor Penetration: Their small size allows deep penetration into tumor tissues, ensuring efficient drug delivery.
- Controlled Drug Release: PNPs enable pH-responsive or enzyme-sensitive drug release, facilitating precise drug release at the tumor site.

Clinical Potential:

Polymeric nanoparticles are being explored for co-delivery of multiple drugs to overcome multidrug resistance (MDR) in cancer cells. Their ability to bypass efflux pumps and improve drug retention in tumors makes them highly promising for next-generation cancer therapies. [11]

2.3 Dendrimers: [12]

Dendrimers are highly branched, three-dimensional polymeric structures with a well-defined architecture that allows for precise drug conjugation and targeted delivery. Their multiple functional groups on the surface enable the attachment of drugs, imaging agents, and targeting ligands, making them multifunctional nanocarriers.

Advantages of Dendrimers:

- High Drug Loading Capacity: Their branched structure allows for multiple drug molecules to be encapsulated or conjugated.
- Targeted Drug Delivery: Functionalized dendrimers can be designed to recognize tumorspecific receptors, improving drug selectivity.
- Enhanced Solubility and Stability: Poorly water-soluble drugs can be encapsulated within dendrimers, increasing their bioavailability.

Potential in Cancer Therapy:

Dendrimers have been studied for delivering anticancer drugs, gene therapy agents, and imaging probes. Their flexibility in design and ability to overcome biological barriers make them a promising nanocarrier system in oncology.

2.4 Metallic Nanoparticles: [13]

Metallic nanoparticles, particularly those made of gold, silver, and iron oxide, have gained significant attention in cancer therapy due to their unique optical, thermal, and magnetic properties.

Gold Nanoparticles (AuNPs):

Gold nanoparticles are extensively used due to their biocompatibility and photothermal properties. They absorb near-infrared (NIR) light, generating localized heat that selectively destroys cancer cells while sparing normal tissues (photothermal therapy, PTT).

Silver Nanoparticles (AgNPs):

Silver nanoparticles exhibit anticancer and antimicrobial properties, inducing cancer cell apoptosis through reactive oxygen species (ROS) generation. However, their potential toxicity to normal tissues requires further investigation.

Iron Oxide Nanoparticles (IONPs):

Iron oxide nanoparticles are used in magnetic hyperthermia therapy, where they generate heat upon exposure to an external magnetic field, selectively killing tumor cells. They also serve as contrast agents in magnetic resonance imaging (MRI), aiding in cancer diagnosis.

Advantages of Metallic Nanoparticles:

- Precise Tumor Ablation: Photothermal and magnetic hyperthermia approaches enable localized cancer cell destruction.
- Minimized Drug Resistance: Unlike conventional chemotherapy, nanoparticle-mediated thermal therapies do not rely on drug uptake, reducing resistance development.
- Dual Functionality: These nanoparticles can be used for both diagnostic imaging and therapy (theranostics).

Metallic nanoparticles hold immense potential in non-invasive cancer treatments, providing highly selective, targeted, and minimally toxic approaches.

2.5 Carbon-Based Nanomaterials: [14]

Carbon nanomaterials, including carbon nanotubes (CNTs) and graphene oxide (GO) nanoparticles, have emerged as promising drug delivery vehicles due to their high drug-loading capacity, excellent thermal conductivity, and ability to penetrate cell membranes.

Carbon Nanotubes (CNTs):

CNTs are cylindrical nanostructures with remarkable mechanical and electrical properties. They serve as carriers for anticancer drugs and enable photothermal and photodynamic therapy (PDT) by absorbing NIR light and generating heat.

Graphene Oxide (GO) Nanoparticles:

GO nanoparticles have a large surface area and multiple functional groups, making them suitable for targeted drug delivery and gene therapy. They also exhibit intrinsic cytotoxicity toward cancer cells, enhancing their therapeutic potential.

Advantages of Carbon-Based Nanomaterials:

- High Surface Area: Enables efficient drug loading and delivery.
- Photothermal Therapy Potential: Facilitates localized tumor destruction with minimal damage to surrounding tissues.
- Efficient Cellular Uptake: CNTs and GO easily penetrate cell membranes, ensuring intracellular drug release.

Despite their advantages, biocompatibility and toxicity concerns remain challenges that need to be addressed before their widespread clinical application.

3. Targeted Approaches in Nanomedicine:

Nanomedicine leverages nanoscale materials and delivery systems to enhance therapeutic efficacy while minimizing systemic toxicity. One of the key advantages of nanomedicine is its ability to selectively deliver drugs to diseased tissues, particularly in cancer treatment. This targeted approach is categorized into passive targeting and active targeting, both of which improve drug bioavailability and therapeutic efficiency.



Figure 2: Different nano-particles used in medical sciences.

3.1 Passive Targeting: Enhanced Permeability and Retention (EPR) Effect:

Concept of the EPR Effect

Passive targeting is primarily based on the Enhanced Permeability and Retention (EPR) effect, a phenomenon observed in tumor physiology. Tumors require rapid angiogenesis (formation of new blood vessels) to sustain their uncontrolled growth. However, these newly formed blood vessels tend to have defective architecture, including:

- Increased permeability – Tumor blood vessels contain large gaps between endothelial cells, allowing nanoparticles and macromolecules to extravasate (leak out) into the tumor microenvironment.
- Poor lymphatic drainage – Unlike normal tissues, tumors exhibit impaired lymphatic function, preventing the efficient clearance of nanoparticles and leading to longer retention times.

This unique characteristic enables nanocarriers, such as liposomes, polymeric nanoparticles, dendrimers, and micelles, to passively accumulate in tumor tissues. As a result, the EPR effect enhances drug accumulation at tumor sites while reducing systemic exposure, thereby minimizing toxicity to healthy tissues.

Factors Influencing Passive Targeting

The efficiency of the EPR effect depends on several factors:

1. Nanoparticle Size – Optimal nanocarrier size ranges between 10–200 nm, ensuring effective extravasation while preventing rapid renal clearance.
2. Surface Properties – Nanoparticles coated with hydrophilic polymers, such as polyethylene glycol (PEG), evade immune recognition and prolong circulation time.
3. Tumor Heterogeneity – Not all tumors exhibit the EPR effect equally, as variations in vascular permeability exist among different tumor types.

Despite its advantages, passive targeting alone is insufficient for precise drug delivery due to heterogeneous blood flow and inconsistent vascular permeability in tumors. To overcome these limitations, active targeting strategies have been developed. [15]

3.2 Active Targeting: Ligand-Based Approaches

Principle of Active Targeting

Active targeting involves functionalizing nanoparticles with specific targeting moieties, such as ligands, antibodies, peptides, or aptamers, that recognize and bind to overexpressed receptors on cancer cells. This strategy enhances the specificity of drug delivery and promotes intracellular uptake through receptor-mediated endocytosis.

Examples of Active Targeting Strategies

(a) Folate Receptor Targeting

Folate receptors (FRs) are highly expressed in various cancer types, including ovarian, breast, and lung cancers, while exhibiting limited expression in normal tissues. Folate-conjugated nanoparticles selectively bind to these receptors, facilitating targeted drug delivery.

- Mechanism: Folate-functionalized nanoparticles interact with folate receptors, triggering receptor-mediated endocytosis.
- Example: Liposomal folate-doxorubicin formulations enhance drug accumulation in Overexpressing tumor cells, improving therapeutic outcomes.

(b) HER2-Targeted Therapy

The human epidermal growth factor receptor 2 (HER2) is overexpressed in aggressive breast cancers. Nanoparticles conjugated with trastuzumab (Herceptin®), an anti-HER2 monoclonal antibody, improve drug specificity for HER2-positive cells.

- Mechanism: Trastuzumab-bound nanoparticles bind to HER2 receptors, leading to internalization and targeted drug release inside cancer cells.
- Example: HER2-targeted liposomes loaded with paclitaxel exhibit enhanced cytotoxicity in HER2-positive breast cancer models.

(c) EGFR-Targeted Therapy

The epidermal growth factor receptor (EGFR) is overexpressed in multiple cancers, including lung, colorectal, and head and neck cancers. Targeting EGFR improves drug selectivity and mitigates resistance mechanisms.

- Mechanism: EGFR-targeted nanoparticles bind to the receptor, triggering endocytosis and intracellular drug release.
- Example: EGFR-conjugated gold nanoparticles have been explored for targeted photothermal therapy, inducing localized heat generation to destroy cancer cells. [16]

3.3 Stimuli-Responsive Targeting in Nanomedicine:

Stimuli-responsive targeting enhances drug delivery by triggering drug release in response to specific biological cues such as pH, redox potential, temperature, or enzymes. These smart nanocarriers improve drug selectivity, minimize side effects, and optimize therapeutic outcomes.

1. pH-Sensitive Nanocarriers

Tumor tissues have a more acidic microenvironment (pH ~6.5–6.8) compared to normal tissues (pH 7.4). pH-sensitive nanoparticles remain stable in circulation but degrade in acidic conditions, releasing drugs at the tumor site.

Examples:

- pH-sensitive polymeric nanoparticles (PLGA, poly(β-amino esters)) break down at low pH.
- Acid-labile drug linkers (hydrazone, Schiff base bonds) trigger controlled release.
- pH-responsive liposomes enhance intracellular drug delivery.

Application: Doxorubicin-loaded pH-sensitive liposomes target acidic tumor environments, reducing cardiotoxicity.

2. Redox-Responsive Drug Carriers

Tumors have higher intracellular glutathione (GSH) levels (2–10 mM) compared to normal tissues (2–10 μM). Redox-sensitive nanoparticles break down in response to GSH, ensuring intracellular drug release.

Examples:

- Disulfide-bonded polymeric nanoparticles cleave in high-GSH environments.
- Redox-sensitive micelles disassemble, improving drug bioavailability.

Application: Paclitaxel-loaded disulfide-bonded nanoparticles enhance tumor-specific drug release.

3. Temperature-Responsive Nanocarriers

Tumors exhibit higher temperatures (40–42°C) than normal tissues (37°C) due to metabolic activity. Thermo-sensitive nanocarriers release drugs upon exposure to localized hyperthermia.

Examples:

- Thermo-sensitive liposomes (DPPC-based) release drugs at mild hyperthermia.
- PNIPAM-based polymers undergo temperature-induced sol-gel transition.

Application: Thermosensitive doxorubicin liposomes release drugs in hyperthermic tumor regions. 4. Enzyme-Responsive Drug Delivery
Tumors overexpress specific enzymes (MMPs, cathepsins, hyaluronidases) that degrade the extracellular matrix. Enzyme-responsive nanoparticles disassemble upon enzyme interaction, ensuring localized drug release.

Examples:

- MMP-sensitive nanoparticles degrade in MMP-rich tumors.
- Hyaluronic acid-coated carriers release drugs in response to hyaluronidase.

Application: MMP-sensitive PEGylated nanoparticles selectively release chemotherapy drugs in tumors. [17]

4. Recent Advances in Nanomedicine for Cancer Therapy

Nanomedicine has revolutionized cancer treatment by improving drug delivery, enhancing therapeutic outcomes, and minimizing side effects. Recent innovations include nanoparticle-based immunotherapy,

combination therapy, and theranostic nanoparticles, which integrate therapy and diagnostics for more precise cancer management.

4.1 Immunotherapy with Nanoparticles

Nanoparticles enhance cancer immunotherapy by improving drug stability, bioavailability, and targeted delivery of immune-modulating agents.

1. Immune Checkpoint Inhibitor Delivery

Nanoparticles serve as carriers for immune checkpoint inhibitors (ICIs) such as anti-PD-1 and antiCTLA-4 antibodies, which restore T-cell activity and enhance the immune response against tumors.

Example:

- Polymeric nanoparticles delivering anti-PD-1 antibodies improve immune activation and reduce off-target toxicity.

2. Lipid-Based Nanoparticles for Cancer mRNA Vaccines

Lipid nanoparticles (LNPs) are used to deliver mRNA vaccines encoding tumor antigens, stimulating an anti-tumor immune response.

Example:

- mRNA-based cancer vaccines (similar to COVID-19 vaccines) packaged in LNPs induce tumor-specific immunity and enhance cancer immunotherapy. [18]

4.2 Combination Therapy

Combination therapy in nanomedicine enhances treatment efficacy by targeting multiple pathways simultaneously.

1. Co-Delivery of Chemotherapy and Gene Therapy

Nanoparticles enable the simultaneous delivery of chemotherapeutic agents (e.g., doxorubicin, paclitaxel) and gene therapy molecules (e.g., siRNA, miRNA) to overcome drug resistance and improve tumor targeting.

Example:

- Liposomal nanoparticles co-delivering doxorubicin and siRNA silence genes responsible for drug resistance, improving treatment effectiveness.

2. Synergistic Therapy (Photothermal & Photodynamic Therapy)

Nanoparticles can enhance photothermal therapy (PTT) and photodynamic therapy (PDT) by converting light energy into heat (PTT) or generating reactive oxygen species (PDT) to kill cancer cells. [19]
Example:

 Gold nanorods absorb near-infrared (NIR) light, generating localized heat for photothermal therapy in solid tumors.

4.3 Theranostic Nanoparticles

Theranostic nanoparticles combine diagnostic and therapeutic functions within a single nanoplatform, enabling real-time imaging and targeted treatment.

Examples:

1. Gold Nanoparticles – Used for simultaneous imaging (X-ray contrast) and photothermal therapy.
2. Iron Oxide Nanoparticles – Serve as MRI contrast agents while delivering anticancer drugs.
3. Quantum Dots – Enable fluorescence imaging and targeted drug delivery in tumors.

Application:

 Gold nanoparticle-based theranostics improve tumor visualization and destruction using laser-induced hyperthermia. [20]

5. Challenges and Future Perspectives in Nanomedicine

Despite advancements, nanomedicine faces challenges in biocompatibility, large-scale manufacturing, and clinical translation. Addressing these issues is crucial for widespread adoption.

5.1 Key Challenges [21]

1. Biocompatibility and Toxicity

- Risk of organ accumulation, immune activation, and unpredictable degradation.
- Solution: Use biodegradable materials and stealth coatings (e.g., PEGylation) to enhance safety.

2. Scalability and Manufacturing

- Difficulties in large-scale production, high costs, and regulatory barriers.
- Solution: Implement AI-driven synthesis and GMP-compliant production for consistency.

3. Clinical Translation

- Limited human trial data, challenges in biodistribution, and regulatory approval.
- Solution: Focus on long-term safety studies and standardized regulatory frameworks.

5.2 Future Perspectives [22]

- Personalized Nanomedicine: Tailoring nanoparticles for patient-specific treatments.
- AI-Driven Nanoparticle Design: Optimizing formulations for enhanced precision.

- Hybrid Nanosystems: Combining multiple functionalities for better targeting and efficacy.

Conclusion:

Nanomedicine has transformed cancer therapy by offering targeted, efficient, and minimally toxic treatment strategies. Passive, active, and stimuli-responsive targeting mechanisms improve drug accumulation at tumor sites, enhancing therapeutic outcomes. Furthermore, emerging innovations like immunotherapy, combination therapy, and theranostic nanoparticles are paving the way for more precise and effective treatments. However, challenges such as biocompatibility concerns, production scalability, and regulatory hurdles must be addressed to ensure successful clinical translation. Future advancements in personalized medicine, AI-driven formulations, and hybrid nanosystems hold great promise in overcoming these barriers, driving nanomedicine toward mainstream clinical applications for cancer therapy.

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7-30.
2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-74.
3. Luqmani YA. Mechanisms of drug resistance in cancer chemotherapy. Med Princ Pract. 2005;14(Suppl 1):35-48.
4. Zhao L, Wientjes MG, Au JL. Resistance to chemotherapy: mechanisms, and strategies for overcoming resistance. AACR J Clin Cancer Res. 2009;15(23):7471-8.
5. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2(12):751-60.
6. Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov. 2008;7(9):771-82.
7. Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science. 2004;303(5665):1818-22.
8. Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev. 2002;54(5):631-51.
9. Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. ACS Nano. 2009;3(1):16-20.
10. Barenholz Y. Doxil®—the first FDA-approved nano-drug: lessons learned. J Control Release. 2012;160(2):117-34.
11. Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Préat V. PLGA-based nanoparticles: an overview of biomedical applications. J Control Release. 2012;161(2):505-22.
12. Kesharwani P, Jain K, Jain NK. Dendrimer as nanocarrier for drug delivery. Prog Polym Sci. 2014;39(2):268-307.
13. Huang X, Jain PK, El-Sayed IH, El-Sayed MA. Gold nanoparticles: interesting optical properties and recent applications in cancer diagnostics and therapy. Nanomedicine. 2007;2(5):681-93.
14. Chowdhury S, Balasubramanian K, Ghosh SS. Carbon nanomaterials: a new paradigm in biomedical applications. RSC Adv. 2021;11(7):3610-34.

15. Maeda H, Nakamura H, Fang J. The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv Drug Deliv Rev. 2013;65(1):71-9.
16. Danhier F. To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release. 2016;244:108-21.
17. Liu J, Huang Y, Kumar A, Tan A, Jin S, Mozhi A, Liang XJ. pH-sensitive nano-systems for drug delivery in cancer therapy. Biotechnol Adv. 2014;32(4):693-710.
18. Zhang Z, Shen W, Ling J, Yan Y, Hu J, Fan Y. Nanoparticle-based delivery of immune checkpoint inhibitors for cancer immunotherapy. Nanoscale. 2020;12(42):21534-48.
19. Torchilin VP. Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. Nat Rev Drug Discov. 2014;13(11):813-27.
20. Mura S, Nicolas J, Couvreur P. Stimuli-responsive nanocarriers for drug delivery. Nat Mater. 2013;12(11):991-1003.
21. Kumari S, Badana AK, Murali Mohan G, Shailender G, Malla RR. Reactive oxygen species: A key constituent in cancer survival. Biomed Pharmacother. 2018;103:1096-107.
22. Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: Progress, challenges, and opportunities. Nat Rev Cancer. 2017;17(1):20-37.